Clinical Calculators

Liver Transplant Priority Scores (MELD 3.0 / Child-Pugh)

MELD 3.0 broken out term by term, including the female sex coefficient and the two albumin terms; MELD-Na and the original pre-sodium MELD for comparison; and the Child-Pugh class. Each figure names the publication or policy it came from. Units are declared on every field and an impossible value stops the calculation instead of producing a number.

Read this first · scope and limits

Decision support for qualified clinicians. This page reproduces published scoring systems and published allocation policy; it does not diagnose, does not triage, does not allocate an organ and is not a substitute for clinical judgement, the transplant programme’s own assessment or current OPTN policy. It is not for patient self-assessment. Nothing entered here is transmitted or stored anywhere.

Every coefficient, bound, cut-off and outcome figure below is reproduced from the publication or policy named beside it, with its as-of date. Where a figure could not be confirmed against a primary, registry or society source it was left out rather than estimated, and the omission is stated in the sources card. Where two authorities disagree, both are shown. No dose appears anywhere on this page.

AnalyteUnit the equations useOther unit acceptedConversion applied
Total bilirubinmg/dLmicromol/Lmicromol/L divided by 17.1 gives mg/dL
Serum creatininemg/dLmicromol/Lmicromol/L divided by 88.4 gives mg/dL
Serum albuming/dLg/Lg/L divided by 10 gives g/dL
Serum sodiummmol/LmEq/Lnumerically identical for a monovalent ion
INRratioratiodimensionless

Both scores are defined on conventional units. Molar conversions are exact ratios of molecular weight and are applied before any bound is tested.

1 · Laboratory values
Required by MELD 3.0, MELD-Na and Child-Pugh.
A ratio, not a time. On warfarin the INR is not a liver measurement and both MELD scores are distorted.
Ceiling differs between the two scores: 3.0 mg/dL for MELD 3.0, 4.0 mg/dL for MELD-Na.
Clamped to 125 to 137 mmol/L before use. mmol/L and mEq/L are numerically identical here.
Used by MELD 3.0 and by Child-Pugh. MELD-Na has no albumin term.
MELD 3.0 carries a 1.33 coefficient for female candidates. OPTN applies MELD to candidates aged 12 and older and requires an albumin value for all of them; the 1.33 female term applies to adult candidates, that is those registered at or after age 18.
Two or more dialysis treatments in the previous 7 days, or 24 hours of continuous veno-venous haemodialysis in the previous 7 days. This sets creatinine to each score’s ceiling.
2 · Clinical findings for Child-Pugh
A bedside judgement, which is one reason Child-Pugh is not used for allocation.
Pugh’s original variable was the prothrombin time prolongation over control. The INR columns are the modern substitution, and the two reproductions read for this tool disagree about their upper cut-off, so both are computed.
Accepted input ranges

These acceptance limits are this tool’s own input guard, not a guideline threshold and not a reference range. They exist so that a value entered in the wrong unit is refused instead of being pushed through the equation. When a value falls outside them the tool prints nothing and names the field.

FieldAcceptedWhy
Total bilirubin0.1 to 60 mg/dLA number above 60 mg/dL is almost always a micromol/L value typed into the mg/dL field.
INR0.5 to 20 ratioINR is a ratio. A value near 12 or 90 is usually a prothrombin time in seconds.
Serum creatinine0.1 to 25 mg/dLA number above 25 mg/dL is almost always a micromol/L value typed into the mg/dL field.
Serum sodium100 to 180 mmol/LSerum sodium outside 100 to 180 mmol/L is not a survivable measurement and is treated here as a typing error.
Serum albumin0.5 to 7.0 g/dLA number above 7 g/dL is almost always a g/L value typed into the g/dL field.
Prothrombin time prolongation0 to 60 secondsThis field wants the prolongation over control in seconds, not the absolute prothrombin time.
Result
Allocation context · what the score does not do

The score is only the first half of US liver allocation. What follows is the published policy context, each statement carrying its source and year. This tool does not compute an exception score.

Which score is in force. OPTN adopted MELD 3.0 in July 2023, replacing MELD-Na. A three-month analysis after implementation showed overall transplant rates increased significantly for female candidates.

Source: Sandhu S, Goldberg D. Update on Organ Allocation and Liver Transplantation. Gastroenterol Hepatol (N Y) 2025;21(7). As of 2025.

Reported scale. MELD is reported to candidates as a scale from 6, least ill, to 40, gravely ill, and expresses how urgently a transplant is needed within the next three months.

Source: United Network for Organ Sharing, Questions and Answers for Transplant Candidates about MELD and PELD (patient brochure, read in full). The brochure predates both MELD-Na and MELD 3.0; the 6 to 40 reporting scale has been carried through both revisions. As of brochure dated 2008; scale unchanged.

Order of offers. Under acuity-circle allocation a liver is offered first to Status 1A and 1B candidates within 500 nautical miles of the donor hospital. It then goes to candidates with MELD 37 or higher within 150 nautical miles, then 250, then 500, and the sequence repeats for descending thresholds of 33 to 36, 29 to 32, 15 to 28, and below 15.

Source: Sandhu S, Goldberg D. Update on Organ Allocation and Liver Transplantation. Gastroenterol Hepatol (N Y) 2025;21(7). As of 2025.

The MELD 15 line. MELD 15 is the long-standing allocation boundary: candidates below 15 sit in the lowest priority tier of the sequence.

Source: Sandhu S, Goldberg D. Update on Organ Allocation and Liver Transplantation. Gastroenterol Hepatol (N Y) 2025;21(7). As of 2025.

Why exception points exist. The laboratory score does not capture ascites, encephalopathy, sarcopenia, portal hypertensive complications, hepatocellular carcinoma or the other diagnoses that make a candidate urgent without deranging these five values. Where a programme believes the laboratory score understates urgency it submits an exception request.

Source: Kim WR et al., Gastroenterology 2021 (variables in the model); Latt NL, Niazi M, Pyrsopoulos NT. Liver transplant allocation policies and outcomes in United States: A comprehensive review. World J Methodol 2022;12(1):32-42. As of 2021 and 2022.

Who decides. The National Liver Review Board was established in 2019, replacing the regional review boards, and standardised the criteria for the conditions that qualify for an exception.

Source: Sandhu S, Goldberg D. Gastroenterol Hepatol (N Y) 2025;21(7); Latt NL et al. World J Methodol 2022;12(1):32-42. As of 2019 policy, described 2022 and 2025.

How an exception score is set. A standardised exception is indexed to the median MELD at transplant, MMaT, for the area, minus 3 points. Since acuity circles began in February 2020 that median has been computed over a 250 nautical mile radius around the transplant hospital; before that it was computed by donor service area.

Source: AASLD Liver Fellow Network, Why do we use the MELD score, Part 2: exception points are ‘the median MELD score at transplant (MMaT) within a 250 nautical mile radius of the transplant minus 3’; Bernards S, Hirose R, Yao FY, et al. Liver Transpl 2021;28(3):376-385. As of accessed 2026-08-01; policy from May 2019.

How often the index moves. MMaT is recalculated from the previous 12 months of transplants and republished for every donor hospital roughly every 6 months, so the same exception rule yields a different number at different times and places. The most recent published update took effect on 2026-03-25.

Source: Latt NL et al. World J Methodol 2022;12(1):32-42; OPTN news notice, updated Median MELD at Transplant values effective 2026-03-25. As of 2026-03-25.

Hepatocellular carcinoma. HCC candidates wait six months on their laboratory score before any exception score is granted, a rule in force since 2015. Since May 2019 the exception granted after that wait is MMaT minus 3 for the candidate’s area.

Source: Bernards S, Hirose R, Yao FY, et al. Liver Transpl 2021;28(3):376-385; Parikh ND, Singal AG. Clin Liver Dis (Hoboken) 2016;7(5):97-100. As of 2015 and 2019 policies.

What HCC exceptions looked like before. Under the scheme described in 2016, an eligible HCC candidate was listed at the laboratory score, awarded 28 exception points after the six-month wait, and then rose every three months to a maximum of 34. That fixed ladder no longer applies; it is shown because scores recorded before May 2019 were generated by it.

Source: Parikh ND, Singal AG. Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;7(5):97-100. As of 2016.

Methodology and sources

Rule this page follows. No coefficient, bound, cut-off, band or outcome figure appears here unless it was read off a primary publication, a registry policy document, a national formulary body or a peer-reviewed professional reference text. Figures that could not be confirmed that way were omitted rather than approximated or interpolated, and every omission is listed under ‘omitted’. Where two authorities genuinely disagree, both are carried here with attribution and the tool prints both instead of averaging them. No dose appears anywhere.

Where authorities disagree. The two reproductions read here disagree on the upper coagulation cut-off. The NHS Specialist Pharmacy Service tabulates INR 1.7 to 2.3 for 2 points and above 2.3 for 3 points; StatPearls tabulates INR 1.7 to 2.2 for 2 points and above 2.2 for 3 points. Both are printed. They differ only for an INR between 2.2 and 2.3, and the tool says so when the entered INR falls in that window. The three-month mortality figures also come from three different vintages of the score and three different cohorts, so all three are printed side by side and none is blended into a single number.

Deliberately left out.

  • Any computed exception score. An exception score depends on the median MELD at transplant for a specific donor hospital on a specific date. OPTN publishes that table per hospital and reissues it about every 180 days, and it could not be retrieved in machine-readable form on 2026-08-01, so no MMaT value and no MMaT-derived score is printed. Only the published rule is shown.
  • The intermediate Wiesner 2003 mortality bands. The Gastroenterology 2003 abstract states 1.9 percent for MELD under 9 and 71.3 percent for MELD 40 or more. The 10 to 19, 20 to 29 and 30 to 39 figures could not be read from the primary, and the secondary reproductions found disagree with one another on the same paper, so none is printed.
  • PELD. This tool is adult only. PELD and PELD-creatinine are separate equations with different variables including growth failure and age under one year, and the current PELD-Cr coefficients could not be read off a policy document on 2026-08-01.
  • Status 1A and 1B qualifying criteria. The published summaries reachable on 2026-08-01 describe the priority Status 1A and 1B receive but do not reproduce the qualifying criteria in full. The tool therefore states where Status 1A and 1B sit in the offer sequence and does not attempt to test whether a patient qualifies.
  • Post-transplant survival, waiting-list drop-off and any centre-specific figure. These vary by centre, era and indication, and no source giving them at the granularity a calculator would need could be verified.
  • Any drug, dose or dose adjustment. The NHS Specialist Pharmacy Service, whose Child-Pugh table this tool implements, states on the same page that there are no validated scoring systems for determining medication dosing in cirrhosis. No dose appears anywhere on this page.
  • MELD-Lactate, GEMA-Na, ReMELD-Na and other proposed successors. None of them is an OPTN allocation score, and this tool is about allocation priority. Including them would imply a standing they do not have.

Sources.

  • MELD 3.0 equation, bounds, cohort and concordance. Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, Wood NL, Gentry SE, Kwong AJ. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology 2021;161(6):1887-1895.e4. As of 2021; adopted by OPTN for liver allocation in July 2023.
  • date MELD 3.0 entered OPTN allocation. Sandhu S, Goldberg D. Update on Organ Allocation and Liver Transplantation. Gastroenterol Hepatol (N Y) 2025;21(7): ‘In July 2023, the OPTN updated its policy and incorporated the MELD 3.0 score, with a 3-month analysis showing that overall transplant rates significantly increased for females following implementation.’ As of July 2025.
  • MELD-Na formula, sodium clamp, dialysis rule and the greater-than-11 trigger. OPTN Policy 9.1 (MELD score), serum-sodium version approved by the OPTN/UNOS Board in July 2014 and effective 2016-01-11. As of effective 2016-01-11, superseded for allocation in July 2023.
  • MELD 3.0 estimated 90-day survival function. University of Washington Hepatitis C Online and Hepatitis B Online, MELD 3.0 clinical calculator, which publishes this function and attributes it to Kim WR et al., Gastroenterology 2021;161:1887-95. As of accessed 2026-08-01.
  • MELD 3.0 three-month mortality bands. Merck Manual Professional Edition, table ‘MELD Scores and Mortality’, which cites Kim WR et al., Gastroenterology 2021;161(6):1887-1895.e4 and Lim J, Kim JH, Lee A, et al., Gut Liver 2025;19(3):427-437. As of accessed 2026-08-01.
  • original MELD waiting-list mortality, two bands only. Wiesner R, Edwards E, Freeman R, et al.; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124(1):91-96. Abstract read verbatim. As of 2003.
  • Child-Pugh, original modification. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646-649. As of 1973.
  • Child-Pugh, parameter table and class ranges implemented here. NHS Specialist Pharmacy Service. Calculating and using the Child-Pugh score. The same page states that there are no validated scoring systems to determine appropriate medication dosing in patients with liver cirrhosis. As of accessed 2026-08-01.
  • Child-Pugh, cross-check of cut-offs, the prothrombin-time option, and the class outcome figures. Tsoris A, Marlar CA. Use of the Child Pugh Score in Liver Disease. StatPearls, NCBI Bookshelf NBK542308. As of accessed 2026-08-01.
  • Allocation context. Sandhu S, Goldberg D. Update on Organ Allocation and Liver Transplantation. Gastroenterol Hepatol (N Y) 2025;21(7). As of 2025.
  • Allocation context. United Network for Organ Sharing, Questions and Answers for Transplant Candidates about MELD and PELD (patient brochure, read in full). The brochure predates both MELD-Na and MELD 3.0; the 6 to 40 reporting scale has been carried through both revisions. As of brochure dated 2008; scale unchanged.
  • Allocation context. Kim WR et al., Gastroenterology 2021 (variables in the model); Latt NL, Niazi M, Pyrsopoulos NT. Liver transplant allocation policies and outcomes in United States: A comprehensive review. World J Methodol 2022;12(1):32-42. As of 2021 and 2022.
  • Allocation context. Sandhu S, Goldberg D. Gastroenterol Hepatol (N Y) 2025;21(7); Latt NL et al. World J Methodol 2022;12(1):32-42. As of 2019 policy, described 2022 and 2025.
  • Allocation context. AASLD Liver Fellow Network, Why do we use the MELD score, Part 2: exception points are ‘the median MELD score at transplant (MMaT) within a 250 nautical mile radius of the transplant minus 3’; Bernards S, Hirose R, Yao FY, et al. Liver Transpl 2021;28(3):376-385. As of accessed 2026-08-01; policy from May 2019.
  • Allocation context. Latt NL et al. World J Methodol 2022;12(1):32-42; OPTN news notice, updated Median MELD at Transplant values effective 2026-03-25. As of 2026-03-25.
  • Allocation context. Bernards S, Hirose R, Yao FY, et al. Liver Transpl 2021;28(3):376-385; Parikh ND, Singal AG. Clin Liver Dis (Hoboken) 2016;7(5):97-100. As of 2015 and 2019 policies.
  • Allocation context. Parikh ND, Singal AG. Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;7(5):97-100. As of 2016.

Fact base built 2026-08-01, scheduled for re-verification by 2026-11-01. Nothing on this page calls a network, loads a font, loads an image or sets a cookie; the arithmetic runs entirely in this browser, and the rating stars and the theme choice are stored in this browser only.

Was this calculator helpful?